IGF1R and rhabdomyosarcoma: In parallel, preclinical studies demonstrated that IGF1R inhibition with either mAbs or TKIs activated YES kinase, a member of the SRC family tyrosine kinases (SFKs), as a resistance pathway in rhabdomyosarcoma cell lines and xenografts [179].